TABLE 3.
Univariate analysis of factors associated with 7-Day microbiological clearance in the 115 patients with CRKP infection.
| Total | Failure | Clearance | p-value | |
|---|---|---|---|---|
| (n = 115) | (n = 83) | (n = 32) | ||
| Demographic characteristics | ||||
| Age | 63 (51–72) | 64 (53–74) | 61.5 (51–69) | 0.851 |
| Gender | 0.948 | |||
| Female | 39 (33.9%) | 21 (65.6%) | 11 (34.4%) | |
| Male | 76 (66.1%) | 55 (66.3%) | 28 (33.7%) | |
| Weight (Kg) | 65 (55–70) | 65 (55–70) | 65 (55–71.13) | 0.544 |
| BMI | 23.11 (19.92–25.35) | 23.11 (19.76–25.39) | 23.26 (20.42–25.25) | 0.844 |
| Comorbidity | ||||
| Hypertension | 51 (44.3%) | 25 (39.7%) | 8 (53.3%) | 0.336 |
| Malignancy | 33 (28.7%) | 30 (36.1%) | 3 (9.4%) | 0.004 |
| Diabetes mellitus | 31 (27%) | 22 (26.5%) | 9 (28.1%) | 0.861 |
| Cerebrovascular diseases | 19 (16.5%) | 13 (15.7%) | 6 (18.8%) | 0.69 |
| Chronic kidney disease | 19 (16.5%) | 12 (14.5%) | 7 (21.9%) | 0.337 |
| Chronic pulmonary disease | 18 (15.7%) | 17 (20.5%) | 1 (3.1%) | 0.022 |
| Coronary disease | 18 (15.7%) | 13 (15.7%) | 5 (15.6%) | 0.996 |
| Peptic ulcer | 15 (13%) | 13 (15.7%) | 2 (6.3%) | 0.353 |
| Immunocompromised | 12 (10.4%) | 9 (10.8%) | 3 (9.4%) | 1 |
| Chronic liver disease | 10 (8.7%) | 6 (7.2%) | 4 (12.5%) | 0.461 |
| Solid organ transplantation | 6 (5.2%) | 2 (2.4%) | 4 (12.5%) | 0.05 |
| Autoimmune disease | 5 (4.3%) | 5 (6%) | 0 (0%) | 0.32 |
| Creatinine clearance (ml/min) | 80.01 (44.37–124.08) | 89.78 (53.31–137.30) | 67.83 (34.19–97.85) | 0.007 |
| Severity variables | ||||
| Charlson comorbidity index (≥3) | 45 (39.1%) | 41 (49.4%) | 4 (12.5%) | <0.001 |
| APACHE II score | 14.1 ± 5.51 | 13.81 ± 5.72 | 14.88 ± 4.92 | 0.354 |
| ICU administration | 85 (73.9%) | 63 (75.9%) | 22 (68.8%) | 0.434 |
| Length of hospital stay before CRKP infection (days) | 20 (7–35) | 20 (8–34) | 20 (4–41.5) | 0.309 |
| Length of hospital stay after CRKP infection (days) | 31 (17–61) | 27 (11–56) | 42 (19.5–77.5) | 0.722 |
| Hospital stay (days) | 60 (40–97) | 56 (36–104) | 68 (47–91.5) | 0.897 |
| Infection variables | ||||
| Hospital-acquired infection | 79 (95.2%) | 30 (93.8%) | 109 (94.8%) | 0.67 |
| Number of infection site | 2 (1–2) | 2 (1–2) | 1 (1–2.75) | 0.601 |
| Pneumonia | 66 (57.4%) | 47 (56.6%) | 19 (59.4%) | 0.789 |
| Bloodstream | 58 (50.4%) | 47 (56.6%) | 11 (34.4%) | 0.032 |
| Urinary tract | 12 (10.4%) | 8 (9.6%) | 4 (12.5%) | 0.736 |
| Abdominal | 32 (27.8%) | 20 (24.1%) | 12 (37.5%) | 0.151 |
| Other sties | 15 (13%) | 9 (10.8%) | 6 (18.8%) | 0.353 |
| Concurrent fungal infection | 29 (25.2%) | 26 (31.3%) | 3 (9.4%) | 0.015 |
| Fever | 80 (69.6%) | 57 (68.7%) | 23 (71.9%) | 0.738 |
| White blood cell count, x109 per L | 10.57 (7.04–15.74) | 11.09 (6.74–16.19) | 10.23 (7.29–14.54) | 0.328 |
| Neutrophils count, x109 per L | 8.77 (5.97–13.38) | 9.22 (5.97–14.07) | 8.49 (5.96–10.94) | 0.258 |
| Procalcitonin (μg/L) | 2.3 (0.77–7.19) | 2.57 (0.85–7.43) | 1.96 (0.44–6.55) | 0.561 |
| C-reactive Protein (mg/L) | 90 (25.4173–168) | 91 (26.85–161.00) | 86.36 (20.18–183.75) | 0.279 |
| Prior healthcare history within 90 days of admission | ||||
| Hospitalization | 74 (64.3%) | 58 (69.9%) | 16 (50%) | 0.046 |
| Surgery | 54 (47%) | 38 (45.8%) | 16 (50%) | 0.05 |
| Antibiotic use | 65 (56.5%) | 52 (62.7%) | 13 (40.6%) | 0.033 |
| Treatment characteristic | ||||
| CAZ/AVI | 37 (32.2%) | 14 (16.9%%) | 23 (71.9%) | <0.001 |
| Carbapenems | 52 (45.2%) | 40 (48.2%) | 12 (37.5%) | 0.302 |
| Tigecycline | 24 (20.9%) | 19 (22.9%) | 5 (15.6%) | 0.39 |
| Fosfomycin | 19 (16.5%) | 14 (16.9%) | 5 (15.6%) | 0.872 |
| Cephalosporins | 23 (20%) | 19 (22.9%) | 3 (12.5%) | 0.212 |
| Aminoglycosides | 14 (12.2%) | 10 (12%) | 4 (12.5%) | 1 |
| Quinolones | 13 (11.4%) | 12 (14.6%) | 1 (3.1%) | 0.107 |
| SMZ | 8 (7.1%) | 5 (6.1%) | 3 (9.7%) | 0.508 |
| 1 active antibiotic | 20 (17.4%) | 13 (15.7%) | 7 (21.9%) | 0.431 |
| 2 active antibiotic | 51 (44.3%) | 35 (42.2%) | 16 (50.0%) | 0.449 |
| ≥3 active antibiotic | 44 (38.3%) | 35 (42.3%) | 9 (28.1%) | 0.165 |
| Duration of treatment (days) | 16 (10–25) | 17 (10–26) | 15 (8.25–23.25) | 0.256 |
| Healthcare interventions | ||||
| Mechanical ventilation | 74 (64.3%) | 52 (62.7%) | 22 (68.8%) | 0.541 |
| Vasoactive drugs | 83 (72.2%) | 60 (72.3%) | 23 (71.9%) | 0.965 |
| ECMO | 1 (0.9%) | 1 (1.2%) | 0 (0%) | 1 |
| CRRT | 17 (14.8%) | 9 (10.8%) | 8 (25%) | 1 |
Abbreviations: BMI, Body mass index; CRKP, carbapenem-resistant Klebsiella pneumonia; CAZ/AVI, Ceftazidime-avibactam; SMZ, compound sulfamethoxazole; ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy.